It is the first sodium-glucose co-transporter 2 inhibitor to be approved to treat adults with New York Heart Association’s functional class II-IV heart failure with reduced ejection fraction.
The US Food and Drug Administration has approved a new once-daily oral tablet for the treatment of osteoarthritis pain. The drug also contains a built-in antihypertensive.
